NCT07679776

Brief Summary

  • OCT, OCTA, fundus photography, and fundus autofluorescence ( FAF ) were used to observe the fundus physiological indexes of normal subjects and SLE patients, to explore the differences of subclinical retinal damage in SLE patients with different degrees of disease activity, to summarize the changes of subclinical retina in SLE patients without organic retinopathy, and to evaluate its correlation with disease activity, which is of great significance for improving the prognosis of visual function and improving the quality of life in SLE patients.
  • By evaluating the visual psychophysical indicators, mainly the visual function test results of different colors and different frequencies, reflecting the functional status of the retina and the degree and characteristics of functional impairment in SLE patients with different degrees of disease activity, in order to screen out the clinical markers of SLE fundus lesions, and provide a reliable reference for the prevention and early intervention of visual impairment.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2025

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 24, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 1, 2026

Completed
Last Updated

July 1, 2026

Status Verified

April 1, 2026

Enrollment Period

12 months

First QC Date

April 24, 2026

Last Update Submit

June 30, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • contrast sensitivity

    Day 1

Study Arms (2)

SLE

SLE patients without retinopathy

Control

Normal group

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A total of 50 patients ( 100 eyes ) who met the inclusion criteria were collected from the patients diagnosed with SLE in the Department of Rheumatology and Immunology of the First Affiliated Hospital of Anhui Medical University. Among them, the diagnosis of SLE is based on the 2019 European Rheumatism Association ( EULAR ) / American Rheumatism Association ( ACR ) SLE diagnostic criteria. At the same time, 50 age-matched healthy adults ( 100 eyes ) were recruited as the normal control group.

You may qualify if:

  • the best corrected visual acuity ( BCVA ) of all cases must be ≥ 1.0 according to the international standard visual acuity char;
  • intraocular pressure ( IOP ) in the normal range, namely 10 mmHg ≤ IOP ≤ 21 mmHg ;
  • visual field meter examination center and peripheral visual field without defect ;
  • no degeneration of fundus retina ;

You may not qualify if:

  • obvious abnormality in cranial MRI ;
  • history of glaucoma, cataract, retinal vascular disease, retinitis pigmentosa and other eye diseases ;
  • history of refractive surgery such as corneal refractive surgery and cataract surgery ;
  • other major disease history or systemic lesions affecting the eye ;
  • history of disease affecting cognitive function, can understand and cooperate with the examination.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Location

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief physician, Doctoral supervisor

Study Record Dates

First Submitted

April 24, 2026

First Posted

July 1, 2026

Study Start

January 1, 2025

Primary Completion

December 31, 2025

Study Completion

June 30, 2026

Last Updated

July 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared due to ethical and privacy considerations. Participants did not consent to data sharing in the informed consent form.

Locations